Label expansion is the practice of adding indications, patient populations, lines of therapy, or combinations to a drug's approved or planned labeling. Each addition multiplies the number of patients the same molecule can treat. For an early-stage asset, it is usually the most efficient way to grow value, because the molecule, the manufacturing process, and the safety database are already paid for.
What does label expansion actually mean?
The label is the FDA-approved prescribing information. It states the indication, population, dose, and setting in which a drug may be promoted. Label expansion means changing that text so that more patients fit inside it. The molecule does not change. What changes is the legal and commercial boundary around who can be treated and reimbursed.
Founders tend to think of their asset as one drug for one disease. Investors and partners think of it as a mechanism that may work in several. The gap between those views is where most of the value lives. On a first-in-class biologic for a rare pediatric leukemia, closing that gap moved the potential U.S. addressable market from roughly $200M per year into the multi-billions. I describe that case separately.
How does a supplemental NDA or BLA work?
After approval, a new indication is added through an efficacy supplement to the original application. For a drug, that is a supplemental New Drug Application (sNDA) under 21 CFR 314.70, which requires FDA approval of labeling changes before the product is distributed with the new claim [4]. For a biologic, the equivalent is a supplemental Biologics License Application (sBLA) under 21 CFR 601.12 [5].
The supplement contains the clinical evidence for the new use but relies on the original application for manufacturing, nonclinical, and prior safety data. That is why it is cheaper and faster than a new application. Under the Prescription Drug User Fee Act, FDA's goal is to act on 90% of standard efficacy supplements within 10 months of receipt and on priority supplements within 6 months [6].
Those goals hold up in practice. An analysis of 146 supplemental new indications approved from 2017 to 2019 found a median review of 6 months, and oncology accounted for 53% of them [1]. In 2024, FDA's Office of Oncologic Diseases approved 17 novel cancer drugs and completed 32 other approval decisions expanding the use or population of previously approved drugs [2].
Which expansion routes exist, and what evidence does each need?
Not every expansion is a new disease. The table lists the routes I see most often, the regulatory vehicle, and the evidence FDA typically expects. The evidence column is a generalization. The requirement is set with the review division and depends on the disease, endpoints, and available therapies.
| Expansion route | Example | Regulatory vehicle | Evidence typically needed |
|---|---|---|---|
| New indication | One lymphoma to a second | sNDA or sBLA efficacy supplement | Adequate and well-controlled trial in the new disease |
| Earlier line of therapy | Third-line to first-line | Efficacy supplement | Randomized trial against current standard of care |
| New population | Adult to pediatric | Efficacy supplement; FDA Written Request | Pediatric PK, safety, and efficacy or extrapolation |
| New formulation or route | Intravenous to subcutaneous | Efficacy supplement, or 505(b)(2) NDA in some cases | PK bridging, sometimes a clinical comparison |
| Combination | Monotherapy to a doublet | Efficacy supplement | Trial showing the contribution of each component |
The evidentiary bar for supplements is not uniform. A systematic review of 295 supplemental indications approved from 2005 to 2014 found that only 30% of new-indication supplements were supported by trials with active comparators, and that population expansions had the weakest evidence [7]. That lowers the cost of expansion but invites payer skepticism.
Some routes bring exclusivity. For drugs approved under an NDA, a supplement supported by new clinical investigations essential to approval can earn 3 years of market exclusivity for that change, and orphan indications carry 7 years for drugs and biologics alike [8]. Completing pediatric studies under an FDA Written Request adds 6 months of exclusivity to every patent and exclusivity period for the same active moiety, across all indications [9].
Should you expand before approval or after?
Before approval, expansion means running parallel indications in development. FDA's 2022 guidance on expansion cohorts supports first-in-human oncology trials with multiple, concurrently accruing cohorts that assess different populations and settings within one protocol [10]. Many pipeline-in-a-product strategies begin this way, at far lower cost than separate Phase 2 trials.
After approval, expansion follows a well-worn sequence. Among 374 cancer indications approved from 2003 to 2021, initial approvals were more often accelerated, single-arm, advanced-line monotherapies, while later extensions were more often randomized and moved into earlier lines or combinations [11]. Manufacturers added supplemental indications at a rate of 0.22 per drug-year in the US, for a total of 221 supplemental indications across 129 cancer drugs [12].
The choice is about the timing of proof. Pre-approval expansion is cheaper per indication and lifts valuation earlier, but each added indication also adds burn and dilutes focus. Post-approval expansion is revenue-funded but takes years. When I choose the early version, I map the target biology to larger adjacent populations and generate nonclinical efficacy data in relevant models before Phase 1.
I will be direct about what that does and does not prove. Nonclinical efficacy in a larger population is a hypothesis with data behind it, not a label. It changes how partners and investors model the asset. It does not change the regulatory bar, and each indication still needs its own adequate and well-controlled evidence.
How do investors value a multi-indication asset?
The standard method is risk-adjusted net present value (rNPV), which multiplies each indication's projected cash flows by its probability of reaching approval and discounts the result [13]. The asset value is the sum across indications. A second credible indication therefore adds value before any trial starts, provided the probability assigned to it is defensible.
The probabilities matter more than the market size. Across 2011 to 2020, the likelihood of approval from Phase 1 was 7.9% for all programs, 5.3% for oncology, 23.9% for hematology, and 17.0% for rare disease therapies [14]. An indication with a large population at a 5% probability can be worth less than a small one at 20%, and investors check assumptions against these benchmarks.
Which drugs earn multiple indications? Among 48 solid-tumor drugs first approved by FDA between 2015 and 2020, 58% gained at least one more indication. Drugs first approved in non-rare cancers expanded 69% of the time, versus 11% for rare cancers, and strong early efficacy predicted expansion [3]. Starting in a rare disease can be the fastest route to approval, but expanding from there needs a deliberate biological argument.
What can label expansion not do?
It cannot rescue a weak molecule. A drug with a marginal effect in its first indication rarely finds a stronger one later, and the data show that expansion follows efficacy [3]. It cannot bypass the evidence standard, since each indication is judged separately. And a long list of unproven indications in a pitch deck reads as a lack of focus, not as optionality.
What it can do is raise the ceiling on an asset without changing the asset. That is why I treat indication strategy as core positioning work, started before the IND rather than after launch. The best time to decide what else a molecule might treat is while the nonclinical plan is being written.
If you are weighing which indications to carry into development on a live program, I would welcome the conversation. Reach me at info@hamiltonatlas.com.
References
- Dhodapkar MM, Ross JS, Ramachandran R. US Food and Drug Administration Review Time of Supplemental New Indication Approvals of Drugs and Biologics, 2017 to 2019. JAMA Network Open. 2023;6(6):e2318889.
- U.S. Food and Drug Administration. Oncology Regulatory Review 2024. FDA, 2025.
- Takahashi S, Maeda H. Identifying Factors Associated with the Acquisition of Multiple Indications for Anticancer Drugs. Current Oncology. 2026;33(6):339.
- U.S. Government Publishing Office. 21 CFR 314.70 Supplements and other changes to an approved NDA. Code of Federal Regulations, 2024.
- U.S. Government Publishing Office. 21 CFR 601.12 Changes to an approved application. Code of Federal Regulations, 2024.
- U.S. Food and Drug Administration. Enclosure: PDUFA Reauthorization Performance Goals and Procedures. FDA, 2024.
- Wang B, Kesselheim AS. Characteristics of efficacy evidence supporting approval of supplemental indications for prescription drugs in United States, 2005-14: systematic review. BMJ. 2015;351:h4679.
- U.S. Food and Drug Administration. Frequently Asked Questions on Patents and Exclusivity. FDA, 2025.
- U.S. Food and Drug Administration. Qualifying for Pediatric Exclusivity Under Section 505A of the Federal Food, Drug, and Cosmetic Act: Frequently Asked Questions on Pediatric Exclusivity (505A). FDA, 2024.
- U.S. Food and Drug Administration. Expansion Cohorts: Use in First-In-Human Clinical Trials to Expedite Development of Oncology Drugs and Biologics Guidance for Industry. FDA, 2022.
- Michaeli DT, Michaeli T. Overall Survival, Progression-Free Survival, and Tumor Response Benefit Supporting Initial US Food and Drug Administration Approval and Indication Extension of New Cancer Drugs, 2003-2021. Journal of Clinical Oncology. 2022;40(35):4095-4106.
- Stoelinga J, Bloem LT, Russo M, Kesselheim AS, Feldman WB. Comparing supplemental indications for cancer drugs approved in the US and EU. European Journal of Cancer. 2024;212:114330.
- Yeon J, Kim C, Kang HS, Bae J, Kim JS. Revisiting risk-adjusted Net Present Value: a practical framework for biotechnology valuation. Drug Discovery Today. 2026;31(4):104717.
- Biotechnology Innovation Organization, Informa Pharma Intelligence, QLS Advisors. Clinical Development Success Rates and Contributing Factors 2011–2020. BIO, 2021.